Published in J Virol Methods on April 01, 1981
Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol (1992) 2.14
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun (1983) 1.78
Polymerase chain reaction assay for detection of human cytomegalovirus. J Clin Microbiol (1989) 1.64
Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigens by enzyme-linked immunosorbent assay. J Clin Microbiol (1984) 1.64
Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections. J Clin Microbiol (1984) 1.53
Variations in the cytomegalovirus major immediate-early gene found by direct genomic sequencing. J Clin Microbiol (1992) 1.22
IgG2 deficiency in a healthy blood donor. Concomitant lack of IgG2, IgA and IgE immunoglobulins and specific anti-carbohydrate antibodies. Clin Exp Immunol (1983) 1.17
Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals. Clin Exp Immunol (1990) 1.05
Flow cytometric and morphologic studies of HNK1+ (Leu 7+) lymphocytes in relation to cytomegalovirus carrier status. Clin Exp Immunol (1988) 1.03
Enzyme-linked immunosorbent assay for detection of equine infectious anemia virus p26 antigen and antibody. J Clin Microbiol (1984) 0.99
Enhancive and suppressive effects of cytomegalovirus on human lymphocyte responses in vitro. J Virol (1986) 0.97
Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus. Clin Exp Immunol (1991) 0.94
Evaluation of a synthetic-peptide enzyme-linked immunosorbent assay for immunoglobulin M to human parvovirus B19. J Clin Microbiol (1991) 0.93
Effect of primary Epstein-Barr virus infection on human herpesvirus 6, cytomegalovirus, and measles virus immunoglobulin G titers. J Clin Microbiol (1990) 0.90
Phenotypic study of CD4+ and CD8+ lymphocyte subsets in relation to cytomegalovirus carrier status and its correlate with pokeweed mitogen-induced B lymphocyte differentiation. Clin Exp Immunol (1989) 0.87
Activity of the cytomegalovirus genome in the presence of PPi analogs. J Virol (1985) 0.87
Lymphocyte and IgG responses to different herpes simplex virus antigens in patients with frequent HSV-1 reactivations. Clin Exp Immunol (1988) 0.84
Antiherpesvirus activity and mechanism of action of indolo-(2,3-b)quinoxaline and analogs. Antimicrob Agents Chemother (1988) 0.84
Antibody responses to synthetic peptides from cytomegalovirus phosphoprotein 150. J Clin Microbiol (1992) 0.80
Cytomegalovirus-seropositive children show inhibition of in vitro EBV infection that is associated with CD8+CD57+ T cell enrichment and IFN-γ. J Immunol (2013) 0.80
Acyclic guanosine analogs as inhibitors of human cytomegalovirus. Antimicrob Agents Chemother (1987) 0.80
Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. Clin Diagn Lab Immunol (1997) 0.76
Postpartum activation of autoimmunity: transient increase of total IgG levels in normal women and in women with autoimmune thyroiditis. Clin Exp Immunol (1987) 0.75
Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet (1999) 2.74
Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol (1992) 2.14
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol (1998) 2.06
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 1.80
Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun (1983) 1.78
Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A (1992) 1.77
Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett (1991) 1.73
Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS (1990) 1.71
Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet (1993) 1.68
Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J Med Virol (1989) 1.61
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr (1992) 1.57
Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis (1990) 1.54
Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections. J Clin Microbiol (1984) 1.53
Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol (1987) 1.52
Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology (1980) 1.50
Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG (2000) 1.47
Frequency and specificity of varicella zoster virus IgM response. J Virol Methods (1982) 1.43
Sequence variation within three important cytomegalovirus gene regions in isolates from four different patient populations. J Clin Microbiol (1998) 1.43
Dynamic changes in HIV-1 quasispecies from azidothymidine (AZT)-treated patients. FASEB J (1992) 1.41
Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera. J Virol (1992) 1.39
Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta (1982) 1.33
Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol (1993) 1.32
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother (1986) 1.31
Diagnosis of infectious mononucleosis by the monospot test. Am J Clin Pathol (1969) 1.28
Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis (1986) 1.28
Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen. J Med Virol (1991) 1.26
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol (1992) 1.25
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis (1985) 1.25
Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture. Antimicrob Agents Chemother (1987) 1.25
Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis (1986) 1.22
Variations in the cytomegalovirus major immediate-early gene found by direct genomic sequencing. J Clin Microbiol (1992) 1.22
A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol (1990) 1.21
Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis (1992) 1.20
IgG antibodies to human herpesvirus-6 in children and adults and in primary Epstein-Barr virus infections and cytomegalovirus infections [corrected]. J Virol Methods (1988) 1.20
A novel method for determining the sensitivity of herpes simplex virus to antiviral compounds. J Virol Methods (1983) 1.19
A new peptide for human parvovirus B19 antibody detection. Scand J Infect Dis (1989) 1.19
Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J Immunol (2000) 1.18
Cytomegalovirus DNA detection of an immediate early protein gene with nested primer oligonucleotides. J Virol Methods (1991) 1.18
Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med (1986) 1.18
IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol (1988) 1.16
Inhibition of cytomegalovirus late antigens by phosphonoformate. Intervirology (1980) 1.15
Identification of hepatitis B virus core protein regions exposed or internalized at the surface of HBcAg particles by scanning with monoclonal antibodies. Virology (1994) 1.14
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. Antimicrob Agents Chemother (1989) 1.13
Immunodominant regions within the hepatitis C virus core and putative matrix proteins. J Clin Microbiol (1992) 1.12
A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. J Virol (1992) 1.11
Placental alkaline phosphatase, alphafetoprotein and carcinoembryonic antigen in testicular tumors. Tissue typing by means of cytologic smears. Int J Cancer (1979) 1.11
Epitope mapping of monoclonal antibodies against human immunodeficiency virus type 1 structural proteins by using peptides. J Virol (1989) 1.10
Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrob Agents Chemother (1988) 1.10
The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline. Antiviral Res (1991) 1.10
Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies. Immunology (1991) 1.09
Antibodies to various herpesviruses in sera from patients with sarcoidosis. J Natl Cancer Inst (1971) 1.08
Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation (1984) 1.08
Bone marrow colony-stimulating activity of sera in infectious mononucleosis. Br Med J (1968) 1.08
Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. J Clin Virol (1999) 1.08
Increased levels of interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) mRNA expressing blood mononuclear cells in human HIV infection. Clin Exp Immunol (1994) 1.07
Human and murine B-cells recognize the HBeAg/beta (or HBe2) epitope as a linear determinant. Mol Immunol (1991) 1.06
Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl (1985) 1.05
Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.05
Molecular basis for serological cross-reactivity between enteroviruses. Clin Diagn Lab Immunol (1994) 1.04
Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr (1991) 1.04
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis (1998) 1.04
Immunochemical structure of the carboxy-terminal part of hepatitis B e antigen: identification of internal and surface-exposed sequences. J Gen Virol (1993) 1.04
Biological characterization of paired human immunodeficiency virus type 1 isolates from blood and cerebrospinal fluid. Virology (1989) 1.04
Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan. Vaccine (2001) 1.03
Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine. Eur J Immunol (1997) 1.02
Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology (1980) 1.02
Epitope mapping of the HIV-1 gag region with monoclonal antibodies. Mol Immunol (1990) 1.02
Computer-based virus sensitivity assay and neutralization method. Applications for herpesviruses. J Virol Methods (1983) 1.02
Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120. J Gen Virol (1992) 1.02
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology (2002) 1.02
Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol (1986) 1.01
Conditions for cytomegalovirus stimulation of lymphocytes. Scand J Immunol (1981) 1.00
Lymphocyte proliferation and IgG production with herpesvirus antigens in solid phase. J Virol Methods (1985) 1.00
Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein. Clin Exp Immunol (1993) 0.99
DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine (2007) 0.99
Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology (2001) 0.99
Serological studies on cytomegalovirus infection in relation to infectious mononucleosis and similar conditions. Scand J Infect Dis (1969) 0.99
Infrequent detection of cytomegalovirus and Epstein-Barr virus DNA in synovial membrane of patients with rheumatoid arthritis. J Rheumatol (1998) 0.98
Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis (1989) 0.98
Foscarnet for cytomegalovirus infections. Lancet (1985) 0.98
Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclasses 1, 3 and 4 against herpes simplex virus. Clin Exp Immunol (1988) 0.98